CANNABINOIDS AS ANTIHYPERTENSIVE AGENTS

大麻素作为抗高血压药

• 批准号: 3500707
• 负责人: HARRY G PARS
• 金额: $ 5万
• 依托单位: H. G. PARS LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-08-01 至 1986-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3500707
• 关键词: antihypertensive agents; blood pressure; cannabinoids; cardiovascular disorder chemotherapy; centrally acting drug; clonidine; dosage; drug administration routes; drug adverse effect; drug design /synthesis /production; drug screening /evaluation; hypertension

H. G. Pars Pharmaceutical Laboratories' long-term goal is to develop and market an orally active antihypertensive drug from its series of sulfur and nitrogen cannabinoid analogs. Hypotensive cannabinoids are believed to exert their effects by altering central sympathetic nervous system activity but the exact mechanism of action is not known and may differ from that of antihypertensive agents on the market. Preliminary cardiovascular/behavioral data indicates that four PARS' compounds (SP-119, SP-269, 273 and 276) show a favorable separation of blood pressure lowering activity and adverse side effects. Hypotensive activity in conscious and anesthetized spontaneous hypertensive (SH) and normotensive rats was of long duration and comparable in magnitude to that of Clonidine. During Phase I we will resynthesize the four analogs and perform more extensive evaluations of their antihypertensive activity in SH rats and behavorial effects in mice. The candidate with the best therapeutic ratio, SP-X, will undergo further evaluation in a 20 day repeat dose study. Results will be compared with clonidine data. Successful completion of this project will allow application for Phase II funds for preparing an oral formulation of SP-X, performing pre-clinical studies and conducting early safety and efficacy trials in human subjects.

H. G. Pars制药实验室的长期目标是开发和